Suppr超能文献

成功进行降尿酸治疗后,滑液中尿酸盐结晶消失所需的时间与痛风病程有关。

Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

作者信息

Pascual Eliseo, Sivera Francisca

机构信息

Catedrático de Medicina (Reumatología), Hospital General Universitario de Alicante, Maestro Alonso 109, 03010 Alicante, Spain.

出版信息

Ann Rheum Dis. 2007 Aug;66(8):1056-8. doi: 10.1136/ard.2006.060368. Epub 2007 Jan 12.

Abstract

OBJECTIVES

To determine whether hypouricaemic treatment results in the disappearance of urate crystals from gouty joints and to define the time required.

METHODS

In 18 patients with monosodium urate (MSU) crystal proven gout, and after the initiation of successful serum uric acid (SUA)-lowering treatment, an arthrocentesis of the asymptomatic signal joint (11 knees, 7 first metatarsophalangeal joints) was performed every 3 months to obtain a synovial fluid (SF) sample. The sample was then analysed for the presence of MSU crystals, and the number of crystals/400x field was noted. SUA levels and the duration of gout were also noted.

RESULTS

MSU crystals disappeared from the SF of all 18 joints after reduction of SUA to normal levels. The time required for disappearance ranged from 3 to 33 months; disappearance time correlated with the duration of gout (r(s) = 0.71; p<0.01). The median number of MSU crystals in the SF samples before urate-lowering treatment was 7.5 (2.5-11) crystals/400x field, reducing to 3 (1-6.5) crystals/400x field (p<0.05) at 3 months. Crystal counts continued to decrease after 3 months.

CONCLUSIONS

In gout, reduction of SUA to normal levels results in disappearance of urate crystals from SF, requiring a longer time in those patients with gout of longer duration. This indicates that urate crystal deposition in joints is reversible. Normalisation of SUA levels results in a decrease in the concentration of MSU crystals in SF in the asymptomatic gouty joints. This may partially explain the reduced frequency of gouty attacks when a patient has been treated with SUA-lowering drugs.

摘要

目的

确定降尿酸治疗是否会使痛风关节中的尿酸盐结晶消失,并确定所需时间。

方法

对18例经尿酸钠(MSU)结晶证实的痛风患者,在成功启动降低血清尿酸(SUA)治疗后,每3个月对无症状的标志性关节(11个膝关节,7个第一跖趾关节)进行关节穿刺,以获取滑液(SF)样本。然后对样本进行分析,以检测MSU结晶的存在,并记录每400倍视野下的结晶数量。还记录了SUA水平和痛风病程。

结果

将SUA降至正常水平后,所有18个关节的SF中MSU结晶均消失。消失所需时间为3至33个月;消失时间与痛风病程相关(r(s)=0.71;p<0.01)。降尿酸治疗前SF样本中MSU结晶的中位数为7.5(2.5 - 11)个/400倍视野,在3个月时降至3(1 - 6.5)个/400倍视野(p<0.05)。3个月后结晶计数持续下降。

结论

在痛风患者中,将SUA降至正常水平会导致SF中的尿酸盐结晶消失,病程较长的患者所需时间更长。这表明关节中尿酸盐结晶的沉积是可逆的。SUA水平正常化会使无症状痛风关节中SF内MSU结晶的浓度降低。这可能部分解释了患者接受降尿酸药物治疗时痛风发作频率降低的原因。

相似文献

4
Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout.
Arthritis Rheum. 1986 Dec;29(12):1480-4. doi: 10.1002/art.1780291209.
5
Synovial fluid analysis for diagnosis of intercritical gout.
Ann Intern Med. 1999 Nov 16;131(10):756-9. doi: 10.7326/0003-4819-131-10-199911160-00007.
6
Monosodium urate crystals in asymptomatic knee joints.
J Rheumatol. 1982 Nov-Dec;9(6):967-9.
9
Crystal deposition in the knee and great toe joints of asymptomatic gout patients.
J R Soc Med. 1984 Sep;77(9):747-50. doi: 10.1177/014107688407700907.
10
The added value of synovial fluid centrifugation for monosodium urate and calcium pyrophosphate crystal detection.
Clin Rheumatol. 2017 Jul;36(7):1599-1605. doi: 10.1007/s10067-017-3633-6. Epub 2017 Apr 19.

引用本文的文献

1
From Patents to Progress: Unraveling Gout's Journey Through Clinical Trials and Advancements.
Rev Recent Clin Trials. 2025;20(2):96-112. doi: 10.2174/0115748871308473240926044126.
3
The Hong Kong Society of Rheumatology consensus recommendations for the management of gout.
Clin Rheumatol. 2023 Aug;42(8):2013-2027. doi: 10.1007/s10067-023-06578-9. Epub 2023 Apr 4.
4
Critical appraisal of serum urate targets in the management of gout.
Nat Rev Rheumatol. 2022 Oct;18(10):603-609. doi: 10.1038/s41584-022-00816-1. Epub 2022 Aug 16.
6
Dietary supplements for chronic gout.
Cochrane Database Syst Rev. 2021 Nov 12;11(11):CD010156. doi: 10.1002/14651858.CD010156.pub3.
8
Ethosomal Gel Formulation of Alpha Phellandrene for the Transdermal Delivery in Gout.
Adv Pharm Bull. 2021 Jan;11(1):137-149. doi: 10.34172/apb.2021.015. Epub 2020 Nov 7.
9
The impact of the illness label 'gout' on illness and treatment perceptions in Māori (Indigenous New Zealanders).
BMC Rheumatol. 2020 Apr 15;4:23. doi: 10.1186/s41927-020-00120-z. eCollection 2020.
10
Concurrent validity of provisional remission criteria for gout: a dual-energy CT study.
Arthritis Res Ther. 2019 Jun 21;21(1):150. doi: 10.1186/s13075-019-1941-8.

本文引用的文献

1
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
Ann Rheum Dis. 2008 Jul;67(7):960-6. doi: 10.1136/ard.2007.076232. Epub 2007 Nov 2.
2
Synovial fluid analysis.
Best Pract Res Clin Rheumatol. 2005 Jun;19(3):371-86. doi: 10.1016/j.berh.2005.01.004.
3
Analysis for crystals in synovial fluid: training of the analysts results in high consistency.
Ann Rheum Dis. 2005 Apr;64(4):612-5. doi: 10.1136/ard.2004.027268.
6
Mobilization of gouty tophi by protracted use of uricosuric agents.
Am J Med. 1951 Dec;11(6):765-9. doi: 10.1016/0002-9343(51)90028-9.
7
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Arthritis Rheum. 2002 Aug;47(4):356-60. doi: 10.1002/art.10511.
10
Synovial fluid analysis for diagnosis of intercritical gout.
Ann Intern Med. 1999 Nov 16;131(10):756-9. doi: 10.7326/0003-4819-131-10-199911160-00007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验